Abstract
Cancer development, like most other human diseases, is the consequence of functional cellular alterations that drive to deregulation of tissue homeostasis. These modifications translate into stronger survival abilities and profound re-adjustments of the subtle balance between proliferative rates and regulated cell death programs. Moreover, further alterations in selected cell sub-clones allow specific cells not only to invade into the local surrounding tissue, but also to enter the systemic circulation – via lymphatic or blood vessels – and to establish new cancer colonies in a host organ. Because of the central role that the protein network plays in cellular function and in maintenance of normal cellular homeostasis, proteomics has become an intense focus of study in oncology today. In this context, technological approaches such as Reverse Phase Protein Microarray that utilize small input samples such as fine needle aspirants or tiny core biopsy samples, routinely used for analysis of metastatic lesions, could have a dramatic impact at the bedside as the gatekeeper for therapeutic selection for each patient. Several studies revealed discrepancies between pathway activation in the primary tumor and in the hepatic metastases, indicating an influence not only of the primary tumor but also of the host microenvironment in the development of metastases. These findings highlight the importance of metastatic lesion profile analysis and suggest its potential in selecting patients for therapy. The use of data derived not only from the primary tumor but also from tumors in secondary sites that ultimately drive the course of the disease is fundamental for clinical decision to increase therapeutic efficacy as well as in the development of new, more specific, compounds for the treatment of metastatic cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- FDA:
-
Food and Drug Administration
- IHC:
-
immunohistochemistry
- FPM:
-
forward phase microarrays
- RPPA:
-
reverse phase protein microarrays
- EDT:
-
post-excision delay time
- PDT:
-
processing delay time
- LCM:
-
laser capture microdissection
- EGF:
-
epidermal growth factor
- EGFR:
-
epidermal growth factor receptor
- COX-2:
-
cyclooxygenase 2
References
Leber MF, Efferth T (2009) Molecular principles of cancer invasion and metastasis (review). Int J Oncol 34:881–895
Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274–284
Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer, 453–458
Fidler IJ (2002) The organ microenvironment and cancer metastasis. Differentiation 70:498–505
Yilmaz M, Christofori G, Lehembre F (2007) Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 13:535–541
Gassmann P, Haier J (2008) The tumor cell-host organ interface in the early onset of metastatic organ colonisation. Clin Exp Metastasis 25:171–181
Fidler IJ (2001) Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am 10:257–269, vii–viiii
Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239–252
Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572
Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF et al (2006) Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 95:123–129
Morris M, Iacopetta B, Platell C (2007) Comparing survival outcomes for patients with colorectal cancer treated in public and private hospitals. Med J Aust 186:296–300
Radinsky R (1995) Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 14:323–338
Radinsky R, Ellis LM (1996) Molecular determinants in the biology of liver metastasis. Surg Oncol Clin N Am 5:215–229
Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, Eng JK et al (2001) Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292:929–934
Wulfkuhle J, Espina V, Liotta L, Petricoin E (2004) Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer 40:2623–2632
Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK (2003) Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci USA 100:9330–9335
Dangle PP, Zaharieva B, Jia H, Pohar KS (2009) Ras-MAPK pathway as a therapeutic target in cancer – emphasis on bladder cancer. Recent Pat Anticancer Drug Discov 4:125–136
Rini BI (2009) Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 115:2306–2312
Schenone S, Bruno O, Radi M, Botta M (2009) New insights into small-molecule inhibitors of Bcr-Abl. Med Res Rev. Published online Wiley InterScience. http://www.interscience.wiley.com. doi:10.1002/med.20175
Aguilera DG, Tsimberidou AM (2009) Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 5:281–289
Browne BC, O’Brien N, Duffy MJ, Crown J, O’Donovan N (2009) HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets 9:419–438
Arteaga CL (2003) EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 21:289s–291s
Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM et al (2008) High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 21:1271–1277
Umemura S, Osamura RY (2004) Utility of immunohistochemistry in breast cancer practice. Breast Cancer 11:334–338
Hanna W (2001) Testing for HER2 status. Oncology 61:22–30
Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG (2009) A robust automated measure of average antibody staining in immunohistochemistry images. J Histochem Cytochem. 58:95–107
Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168
Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B et al (2008) A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7:1998–2018
Unlu M, Morgan ME, Minden JS (1997) Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18:2071–2077
Celis JE, Gromov P (2003) Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3:9–15
Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422:198–207
Lin D, Tabb DL, Yates JR 3rd (2003) Large-scale protein identification using mass spectrometry. Biochim Biophys Acta 1646:1–10
Chen CH (2008) Review of a current role of mass spectrometry for proteome research. Anal Chim Acta 624:16–36
Haab BB (2005) Antibody arrays in cancer research. Mol Cell Proteomics 4:377–383
Espina V, Woodhouse EC, Wulfkuhle J, Asmussen HD, Petricoin EF 3rd, Liotta LA (2004) Protein microarray detection strategies: focus on direct detection technologies. J Immunol Methods 290:121–133
Espina V, Mehta AI, Winters ME, Calvert V, Wulfkuhle J, Petricoin EF 3rd et al (2003) Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 3:2091–2100
Charboneau L, Tory H, Chen T, Winters M, Petricoin EF 3rd, Liotta LA et al (2002) Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic 1:305–315
Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V et al (2005) Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4:346–355
Steinitz M, Tamir S (1995) An improved method to create nitrocellulose particles suitable for the immobilization of antigen and antibody. J Immunol Methods 187:171–177
Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL et al (2003) Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3:2142–2146
Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA et al (2003) Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3:2085–2090
Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW et al (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981–1989
Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR et al (1996) Laser capture microdissection. Science 274:998–1001
Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765
Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D et al (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27:2622–2629
Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8:98–101
Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49–54
Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J et al (2008) Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 7:1508–1517
Petricoin EF, 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L et al (2005) Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol 23:3614–3621
Pierobon M, Calvert V, Belluco C, Garaci E, Deng J, Lise M et al (2009) Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer 8:110–117
Belluco C, Mammano E, Petricoin E, Prevedello L, Calvert V, Liotta L et al (2005 July) Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin Chim Acta 357:180–183
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Silvestri, A., Petricoin, E.F., Liotta, L.A., Pierobon, M. (2011). Proteomic Profiling of Hepatic Metastases: Paving the Way to Individualized Therapy. In: Brodt, P. (eds) Liver Metastasis: Biology and Clinical Management. Cancer Metastasis - Biology and Treatment, vol 16. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0292-9_14
Download citation
DOI: https://doi.org/10.1007/978-94-007-0292-9_14
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-0291-2
Online ISBN: 978-94-007-0292-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)